Recent research has illuminated the intricate relationship between genetics and the efficacy of weight-loss medications such as Wegovy and Mounjaro. Findings published in the journal Nature suggest that individuals carrying specific genetic variations related to appetite and digestion may experience significantly greater weight loss when using these drugs. This discovery not only helps explain the variability in outcomes among users but also sheds light on the potential for increased side effects, such as nausea and vomiting.
Understanding the Genetic Link
A study involving 15,000 participants who had previously undergone genetic testing through 23andMe indicates that those with certain genetic variants can lose more weight while on weight-loss medications. On average, participants lost 11.7% of their body weight over approximately eight months, with some individuals shedding as much as 30%.
Professor Ruth Loos from the University of Copenhagen, who contributed to the research, noted that one specific genetic variant was associated with both increased weight loss and heightened instances of nausea. According to her, individuals with this variant could lose an additional 0.76 kilograms (1.6 pounds) on average, and those with two copies of the gene might even double their weight loss.
The prevalence of this variant varies significantly across ethnic groups; 64% of individuals of European descent carry one copy, whereas only 7% of African Americans do.
The Role of Demographics and Behaviour
While genetics play a role, they are just one piece of a larger puzzle. Other factors, including age, sex, and lifestyle choices, significantly influence the effectiveness of these treatments. Previous studies have indicated that women are more than twice as likely as men to achieve a 15% weight loss with Mounjaro. Younger individuals, along with those identifying as white or Asian, also appear to benefit more from these medications, although the reasons behind these disparities are not yet fully understood.
Dr Marie Spreckley from the University of Cambridge emphasised that genetics represents only one aspect of the treatment equation. She stated that behavioural factors, clinical considerations, and the overall treatment regimen play crucial roles in determining outcomes. These include daily exercise, dietary habits, and the support provided during the weight-loss journey.
Future of Precision Medicine in Weight Loss
The findings from this study could pave the way for a more tailored approach to obesity treatment, often referred to as “precision medicine.” This would involve integrating genetic data with other personal health information to optimise the choice of weight-loss medication for individuals. However, experts like Professor Naveed Sattar from the University of Glasgow caution that while the research is compelling, it is still a long way from prompting changes in clinical practice. He stressed the need for more comprehensive trial data to fully understand the balance of benefits and adverse effects associated with these emerging therapies.
Currently, in the UK, it is estimated that around 1.6 million individuals have sought out weight-loss drugs in the past year, primarily through private online pharmacies. The National Health Service (NHS) prescribes Wegovy and Mounjaro to a limited number of patients suffering from obesity-related health issues, highlighting the need for wider accessibility and understanding of these treatments.
Why it Matters
The implications of this research extend beyond individual weight loss; they touch on public health and the ongoing battle against obesity, which is a significant risk factor for numerous chronic conditions. As understanding of the genetic factors influencing weight loss deepens, there is potential for more effective, personalised treatment strategies that could lead to better health outcomes for millions. However, as the medical community strives for advancements in obesity treatment, the need for robust evidence and a holistic approach to patient care remains paramount.
